FDA Grants Differin Epiduo Rx-to-OTC Switch, Expanding Adapalene-Benzoyl Peroxide Access

The FDA's May 22, 2026 approval of Differin Epiduo Acne Gel (adapalene 0.1% / benzoyl peroxide 2.5%) for nonprescription use under NDA 220736 signals a labeling, manufacturing, and distribution realignment for any site currently producing or planning to produce this combination topical. The switch covers adults and adolescents aged 12 and older for the topical treatment of acne.

For QA directors and plant heads, the Rx-to-OTC reclassification triggers a distinct set of 21 CFR Part 211 and OTC monograph-adjacent obligations. Consumer-facing labeling must now meet Drug Facts panel requirements, and any process validation package built around prescription-grade dispensing assumptions will need reassessment against OTC volume and packaging configurations. Stability data supporting shelf conditions typical of retail environments, rather than pharmacy-controlled storage, will require review.

The combination product's history is relevant context. Adapalene 0.1% as a single-agent gel (Differin Gel, NDA 20380/S-010) completed its own Rx-to-OTC switch in July 2016, establishing a regulatory precedent that the agency has now extended to the fixed-dose combination with benzoyl peroxide. Manufacturers familiar with the 2016 single-agent switch will recognise the compliance pathway, though the addition of benzoyl peroxide introduces oxidative stability and compatibility considerations that were absent from the earlier filing.

Regulatory affairs leads should note that 2024 and 2025 produced no switches on the FDA's published list, making the Differin Epiduo approval the first reclassification in two years. That gap does not indicate a slowdown in agency appetite for switches; rather, it reflects the case-by-case evidentiary burden each NDA supplement must satisfy, including consumer-use studies and label comprehension data under the nonprescription drug approval framework.

Sites supplying this product, or evaluating contract manufacturing opportunities in the OTC acne segment, should initiate gap assessments against current OTC GMP expectations and confirm that existing batch records, in-process controls, and packaging line qualifications are adequate for the anticipated shift in production scale and distribution channel.

The approval date of May 22, 2026 sets the compliance clock; manufacturers moving product into retail channels will need documented process validation and updated site master files before first commercial OTC shipment.

Source: FDA Center for Drug Evaluation and Research (CDER), Prescription to Nonprescription Switch List via FDA.gov, May 22, 2026.